secwatch.observer — SEC 8-K summary
======================================

Issuer:     Allogene Therapeutics, Inc. (ALLO)
CIK:        0001737287
Form:       8-K
Filed at:   2026-04-15T23:59:59+00:00
Accession:  0001193125-26-157140
Event type: other_material
Sentiment:  neutral
Materiality: 0.75
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Allogene prices $175M public offering of 87.5M shares at $2.00 per share
------------------------------------------------------------------------

- Offering of 87,500,000 shares at $2.00/share; gross proceeds ~$175M before discounts and expenses.
- Underwriters granted 30-day option to buy up to 13,125,000 additional shares at same price.
- Closing expected on or about April 16, 2026, subject to customary conditions.
- Net proceeds for general corporate purposes including clinical trials and R&D.
- Goldman Sachs, Jefferies, and TD Cowen act as joint bookrunners; Piper Sandler and William Blair also joint bookrunners.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1737287/000119312526157140/0001193125-26-157140-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1737287/000119312526157140/d283634d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-157140

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer